Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00339833 · ClinicalTrials.gov registry record · Phase 4
The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
A Phase 4 study of Diabetes and Type 2 Diabetes, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 4
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT00339833: Completed Phase 4 study of Diabetes and Type 2 Diabetes, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT00339833 is a Phase 4 study of Diabetes and Type 2 Diabetes that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 54 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00339833, a Phase 4 study of Diabetes and Type 2 Diabetes, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
This study, conducted at the Phoenix Indian Medical Center, Phoenix, Arizona, will determine whether reducing subclinical inflammation lessens insulin resistance in healthy, obese volunteers. The study findings may lead to new strategies for preventing type 2 diabetes. In diabetes, blood sugar is higher than normal and can result in serious medical problems, such as blindness and kidney failure. People with subclinical inflammation-inflammation that does not produce symptoms, such as fever, pain, or skin redness-are at increased risk for diabetes. Although the reasons for this are not completely understood, it is known that subclinical inflammation exacerbates insulin resistance, which is a cause of diabetes. Insulin is a hormone that helps control blood sugar, and when it does not work properly, the condition is known as insulin resistance. Normal, healthy volunteers between 18 and 45 years old with a body mass index of at least 30 kg/m2 and who have subclinical inflammation (determined by blood tests) may be eligible for this study. Candidates must be non-smokers and must not have an alcohol or drug problem. Candidates will be screened with a medical history and physical examination, electrocardiogram, and blood and urine tests. Participants will maintain a standard diet and undergo tests and procedures during a 14-day inpatient stay at the Phoenix Indian Medical Center.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Salsalate
Study Locations (1)
Arizona
- NIDDK, Phoenix - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2003-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
What the finished NCT00339833 record still lists
NCT00339833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00339833 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT00339833 about?
NCT00339833 is a clinical study titled "The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers". This study, conducted at the Phoenix Indian Medical Center, Phoenix, Arizona, will determine whether reducing subclinical inflammation lessens insulin resistance in healthy, obese volunteers. The study findings may lead to new strategies for preventing type 2 diabetes. In diabetes, blood sugar is hi...
What is the current status of trial NCT00339833?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2003-03. Estimated completion is 2008-07.
What conditions does trial NCT00339833 study?
This clinical trial studies the following conditions: Diabetes, Type 2 Diabetes.
What interventions are being tested in trial NCT00339833?
The interventions under investigation include: Placebo (DRUG), Salsalate (DRUG).
Who is sponsoring clinical trial NCT00339833?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00339833 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00339833's enrollment target sits among peer trials
54 248th of 338 higher than 91 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
RECRUITING · Phase 4
-
Depression-Diabetes Mechanisms: Urban African Americans
COMPLETED · Phase 4
-
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
COMPLETED · Phase 4
-
Preventing Depression Recurrence in Diabetes
COMPLETED · Phase 4
-
Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia